Trial Profile
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms ATLAS
- Sponsors Clovis Oncology [CEASED]
- 16 Oct 2020 Status changed from completed to discontinued.
- 22 May 2020 This trial has been Discontinued in United Kingdom according to European Clinical Trials Database record.
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium